Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
53
resultados
Última actualización
12/12/2025 [07:55:00]
Resumen de: WO2024161163A2
Declining cerebral blood flow leads to chronic cerebral hypoperfusion which can induce neurodegenerative disorders, such as vascular dementia. The reduced energy supply of the brain impairs mitochondrial functions that could trigger further damaging cellular processes. Altered levels of protein biomarkers are discloses to be useful in the diagnosis of vascular dementia.
Resumen de: MX2025005880A
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain using a tau PET level.
Resumen de: US2022365093A1
Methods of identifying a compound, such as a test compound, and applications thereof are provided. For example, methods of identifying a compound that preferentially affects, increases, or decreases a level of association of a macromolecule with one or more target condensates or methods of identifying a compound that preferentially causes a macromolecule to associate or disassociate with one or more target condensates are provided. Additionally, methods of designing and/or identifying and/or making a compound, or portion thereof, with a desired characteristic are provided.
Resumen de: US2025369989A1
Described herein are detecting methods for conformational disease, aging and proteinopathies, by measuring the presence of b-isox-precipitates and the levels of b-isox-captured proteins in biofluids of healthy individuals and patients. Research identified additional biomarkers, which made it possible to detect, diagnose or treat, a human disease in a human subject by, with or without adding an isoxazole to an obtained biofluid sample, detecting the biomarker. Use of b-iso and/or biomarkers for diagnosing the disease are made possible.
Resumen de: US2025368729A1
Provided herein are modified immunoglobulins comprising an amyloid reactive peptide joined to an antibody, as well as humanized antibodies that bind to human amyloid fibrils and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering a modified immunoglobulin, humanized antibody, or antibody-peptide fusion protein.
Resumen de: AU2025204068A1
Abstract Provided herein are sulfopropanoic acid derivatives or pharmaceutically acceptable salts thereof, for treating a disease characterized by amyloid and amyloid-like aggregates, e.g., Alzheimer's disease.
Resumen de: AU2024249796A1
The present invention relates to protein markers relevant to mild cognitive impairment (MCI) and Alzheimer's disease (AD), especially those detectable in blood samples. Thus, methods and compositions are provided for risk assessment and early diagnosis of MCI and AD based on the analysis of these protein markers. Further provided are methods and compositions useful for evaluating the efficacy of a therapy for MCI or AD.
Resumen de: JP2024170513A
To provide sensor arrays for detecting biomolecules and methods of use.SOLUTION: Recognition of a biomolecular fingerprint from a sample of a subject is combined with ability to determine a disease state of the subject on a continuum of health care. In some aspect, the present invention provides a sensor array comprising a plurality of sensor elements, where the plurality of sensor elements differ from each other in at least one physicochemical property and the plurality of sensor elements comprises at least two sensor elements. In some aspects, each sensor element is bindable to a plurality of biomolecules in a sample to produce a biomolecule corona signature, where each sensor element has a distinct biomolecule corona signature different from others.SELECTED DRAWING: Figure 1
Resumen de: WO2024231628A1
The invention relates to a method for the early in vitro diagnosis of a neurodegenerative disease in a human or an animal subject, the method comprising the step of detecting the presence of at least one marker chosen from among forms derived from amyloid beta peptides (Aβ) chosen from among the oligomers of these peptides and the prefibrillar and fibrillar aggregate forms of these peptides, and forms derived from phosphorylated tau proteins chosen from among the hyperphosphorylated forms of these proteins, the aggregate forms of these proteins and the modified phosphorylated tau proteins resulting from one or more post-translational modifications, the presence of the one or more markers being detected in a stool sample from this subject.
Resumen de: US2025359753A1
Described herein is the use of a visible near infrared (VNIR) hyperspectral imaging system as a non-invasive diagnostic tool for early detection of Alzheimer's disease (AD). Also described herein is the use of a VNIR hyperspectral imaging system in high throughput screening of potential therapeutics against AD.
Resumen de: US2025361504A1
The present disclosure relates, in general, to methods of preparing a spatial proteome and/or transcriptome sequencing library. The spatial proteome and/or transcriptome sequencing library from a biological sample is useful, in some aspects, to determine a genetic profile and help diagnose a subject who has or is at risk of having a disorder, and improve treatment of the subject.
Resumen de: US2025191903A1
Provided are methods for determining the apolipoprotein E (ApoE) phenotype in a sample by mass spectrometry; wherein the ApoE allele(s) present in the sample is determined from the identity of the ions detected by mass spectrometry. In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.
Resumen de: CN120457337A
The present disclosure provides a method of preparing a biosensor for detecting Alzheimer's disease biomarkers, comprising depositing an alumina film on a Si substrate by an atomic layer deposition system to form an Al2O3/Si substrate; depositing an electric contact part Cr/Au on the Al2O3/Si substrate through a thermal evaporator, and forming a source electrode, a drain electrode and a planar grid electrode on the Al2O3/Si substrate; providing double-layer graphene on the Al2O3/Si substrate through thermal annealing in a vacuum environment; performing low-damage plasma treatment (LDPT) on the double-layer graphene with a mixture of oxygen and hydrogen to form a graphene oxide/graphene (GO/G) layered composite material on the Al2O3/Si substrate; an antibody is immobilized on the surface of a GO/G layered composite material by a reaction between an amine group of the antibody and a carboxyl group of GO of the GO/G layered composite material, where the antibody is specific for p-tau217 protein.
Resumen de: US2025355001A1
The invention relates to an in vitro method for detecting a tau protein fragment in a sample from a patient wherein the amino acid sequence of the fragment consists of amino acid residues within residues 113 to 379 of SEO ID NO: 1. The method may use a specific binding molecule, such as an antibody, directed to key epitopes of tau. The invention may find applications in diagnostics of tauopathics.
Resumen de: WO2025240658A1
Neprilysin inhibitors are used for the treatment of patients with Alzheimer's disease or other proteinopenic diseases of the CNS. The patients selected for therapy may be selected based on confirmed biomarker diagnosis of disease, along with a reduced Aβ level.
Resumen de: US2025355002A1
The invention provides antibodies and binding fragments thereof that specifically binds to TDP-43 cryptic exon-encoded neoepitopes, and methods of use thereof. The methods of use include methods of detecting TDP-43 loss of function, methods of detection and/or diagnosing TDP-43 associated diseases, and methods of monitoring disease progression and/or response to therapy. The invention also provides a kit including the antibodies and binding fragments thereof.
Resumen de: US2024310389A1
This document provides methods and materials related to screening for and treating Alzheimer's disease (AD), including late-onset Alzheimer's disease (LOAD).
Resumen de: WO2024148357A2
U-p53 peptide P1 is useful in the determination of the rate of progression of Alzheimer's disease (AD). By quantitating the level of U-p53 peptides in a subject's biological sample, the rate of progression of Alzheimer's disease at the pre-clinical and prodromal stages of the disease in a subject can be determined.
Resumen de: JP2025094219A
To provide TDP-43-specific binding molecules for diagnosing, preventing, ameliorating, and/or treating diseases, disorders, and/or abnormalities associated with TDP-43 aggregates, or TDP-43 proteinopathies.SOLUTION: Provided is a TDP-43 binding molecule that is an antibody or an antigen-binding fragment thereof, which binds misfolded aggregated TDP-43 and non-aggregated physiological TDP-43, or a humanized variant thereof.SELECTED DRAWING: None
Resumen de: US2025346956A1
In some aspects, the present disclosure provides a method for determining a risk or state of a neurodegenerative disease of a subject. In some embodiments, the method compriseses detecting a presence of a biomarker in a biological sample from the subject, wherein the biomarker comprises at least one of: E7EUF1, O94812, P02549, P02730, P05019, P05154, P05546, P13497, P16157, P16452, P17936, P24593, P27918, P35858, P41218, Q12797, Q13214, Q13822, Q8NI99, Q96IY4, Q99715, Q9BXN1, Q9H0B8, or a proteoform thereof. In some embodiments, the method comprises detecting a presence of a biomarker in a biological sample from the subject, wherein the biomarker comprises at least one of: P54803, P14625, P30043, P00742, A0A0D9SG88, Q5TFM2, P54803, P54803-3, P54803-4, P04196, or a proteoform thereof. In some embodiments, the method comprises determining the risk or state of the neurodegenerative disease of the subject based on the presence of the biomarker in the biological sample.
Resumen de: US2025347684A1
Provided herein is a method for treating a human subject with Alzheimer's Disease (AD) having an AD metabolomic phenotype, the method comprising: obtaining or having obtained a blood sample from the human subject with Alzheimer's disease; measuring the levels of metabolites in the blood sample; applying an algorithm to the measured metabolite levels, the algorithm generating a metabolomic score based on a comparison of the measured metabolites levels to reference metabolites levels; identifying the human subject with Alzheimer's Disease as having an AD metabolomic phenotype based on the metabolomic score; wherein the algorithm is selected from a machine learning algorithm, a clustering algorithm, a random forest algorithm, a support vector machines algorithm, a radial basis function algorithm and a combination thereof.
Resumen de: WO2025235473A2
The presently described and claimed technology relates to high-throughput automated methods for the investigation of ApoE isoforms the subsequent prediction of a likelihood of developing a neurodegenerative disease.
Resumen de: WO2025235476A2
The presently described and claimed technology relates to high-throughput automated methods for the investigation of ApoE isoforms the subsequent prediction of a likelihood of developing a neurodegenerative disease.
Resumen de: CA3242558A1
Aspects of the application relate to methods and systems for obtaining information regarding multiple amino acids in a polypeptide based on binding interactions between the polypeptide and one or more amino acid recognizers. Kinetic signature information may be obtained from a series of signal pulses indicative of a series of binding events between one or more amino acid recognizers and an amino acid of a polypeptide (e.g., a terminal amino acid, an internal amino acid). The kinetic signature information (e.g., pulse duration, interpulse duration, recognition segment (RS) duration, intersegment duration) may be used to determine one or more chemical characteristics (e.g., identity, modification) of multiple amino acids of the polypeptide.
Nº publicación: JP2025168412A 07/11/2025
Solicitante:
ニューロクエストリミテッド
Resumen de: MX2024001835A
Compositions and kits for diagnosing and prognosing Alzheimer's Disease (AD) in a human patient include a binding agent such as a monoclonal antibody for a biomarker conjugated to a detectable moiety such as a fluorophore, wherein the biomarker is chosen from CD 163, CD91, CD59, MerTK and other phagocytosis-related molecules. Further compositions and kits employ panels of fluorophore-conjugated monoclonal antibodies for biomarkers including scavenger receptors. Methods for determining the relative expression of biomarkers, diagnosing AD, and determining the efficacy of AD therapeutic candidates such as phagocytosis-promoting agents and scavenger receptor agonists also appear.
BOPI
Sede Electrónica
